Impact of Rapid Molecular Diagnostic Testing on Outcomes of Patients With Vancomycin-Resistant Enterococcal Bacteremia - Takeaways - MDSpire

Impact of Rapid Molecular Diagnostic Testing on Outcomes of Patients With Vancomycin-Resistant Enterococcal Bacteremia

  • By

  • Michael R Hovan

  • Michael J Burkitt

  • Sierra A Derti

  • Judith U Hargrave

  • Angela S De Cordova

  • Matthew S Simon

  • Stephen G Jenkins

  • Lars F Westblade

  • Michael J Satlin

  • December 12, 2025

  • 0 min

Share

  • 1

    Rapid molecular diagnostic testing (RMDT) for vancomycin-resistant enterococci (VRE) bacteremia was implemented in October 2014.

  • 2

    RMDT significantly reduced the median time to active antimicrobial therapy from 32 hours to 21 hours in patients with VRE bacteremia.

  • 3

    There was no significant difference in 30-day mortality rates between patients who underwent RMDT and those who did not.

  • 4

    A subgroup analysis excluding leukemia patients showed RMDT was associated with decreased 30-day mortality, but this finding did not persist in multivariate analysis.

  • 5

    Overall, RMDT improved the speed of treatment initiation for VRE bacteremia but did not demonstrate a clear improvement in clinical outcomes.

Original Source(s)

Impact of Rapid Molecular Diagnostic Testing on Outcomes of Patients With Vancomycin-Resistant Enterococcal Bacteremia

  • by Michael R Hovan, Michael J Burkitt, Sierra A Derti, Judith U Hargrave, Angela S De Cordova, Matthew S Simon, Stephen G Jenkins, Lars F Westblade, Michael J Satlin

  • December 12, 2025

Related Content

Visions for a JACIE Quality Management System 4.0

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

Refining CAR-NK Design

Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.

  • March 4, 2026

  • 2 min